Phase III Velcade survival data

Millennium (MLNM) said that final analysis of the Phase III APEX trial showed a statistically significant survival benefit for multiple myeloma (MM) patients receiving its Velcade bortezomib compared to control. Survival was a secondary endpoint in the international trial, which compared Velcade to high-dose dexamethasone in 670 patients with relapsed MM. In December, an independent data monitoring committee recommended halting the control arm after an interim analysis showed Velcade patients had a statistically significant improvement in time to disease progression, the trial's primary endpoint (see BioCentury Extra, Monday Dec. 15, 2003). ...